Generic Name and Formulations:
Sodium oxybate 500mg/mL; soln; contains sodium 91mg/mL.
Jazz Pharmaceuticals plc
Indications for XYREM:
Excessive daytime sleepiness and cataplexy associated with narcolepsy.
Take on empty stomach. Dilute each dose with 60mL of water. Initially 4.5g/night in two equally divided doses, at bedtime then again 2.5–4hrs later. May increase by 1.5g/night (0.75g/dose) at weekly intervals; usual range: 6–9g/night; max 9g/night. Allow 6hrs before becoming active after last dose. Consider concomitant CNS stimulant use (see full labeling). Hepatic impairment: reduce dose by ½, titrate and monitor closely. Concomitant divalproex sodium: reduce initial Xyrem dose by at least 20%; if already taking divalproex sodium, start Xyrem at lower dose; monitor, adjust accordingly.
Concomitant sedative hypnotics or alcohol. Succinic semialdehyde dehydrogenase deficiency.
CNS depression. Misuse and abuse.
Risk of CNS depression. Abuse potential (monitor). Respiratory dysfunction. History of depression or suicidal ideation (monitor). Consider sodium intake with heart failure, hypertension, renal insufficiency (see full labeling). Hepatic impairment. Drug abusers. Reevaluate every 3 months. Elderly. Labor & delivery. Pregnancy. Nursing mothers.
Antinarcoleptic (CNS depressant).
See Contraindications. CNS depression potentiated by concomitant other CNS depressants (eg, opioids, benzodiazepine, antidepressants, antipsychotics, general anesthetics, muscle relaxants). Potentiated by divalproex sodium.
Nausea, dizziness, vomiting, somnolence, enuresis, tremor; CNS and respiratory depression, sleepwalking, depressive symptoms, confusion, anxiety, other neuropsychiatric reactions.
Only available through the Xyrem REMS Program. For more information call (866) 997-3688.
Soln—180mL (w. oral dispensing syringe)
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Romosozumab: Effective in Men With Osteoporosis
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
- Link Between Oral Diabetes Medications and Bullous Pemphigoid
- Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
- β-Cell Function in Youth With Impaired Glucose Tolerance, T2D